European Medicines Agency Adopts a Positive Opinion on ​Regeneron’s (REGN) Libtayo

​Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy Right Now. On October 17, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the European Medicines Agency adopted a positive opinion for its Libtayo, which treats adults with cutaneous squamous cell carcinoma.

Earlier this month, Libtayo was approved by the FDA to treat patients with cutaneous squamous cell carcinoma who are at high risk of recurrence after surgery and radiation. Management expects the European Commission to announce its final decision on the application in the coming months.

​This positive opinion is supported by results from the treatment’s global Phase 3 C-POST trial, which showed Libtayo reduced the risk of disease recurrence or death by 68% compared to placebo.

​Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that discovers, develops, and commercializes medicines for serious diseases.

While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.